FibroBiologics (FBLG) said Tuesday it has filed a patent application covering methods to treat splenomegaly using a cell-based approach.
"This patent application highlights the potential of fibroblast-based therapies to address immune-related disorders, such as splenomegaly," said FibroBiologics Chief Executive Pete O'Heeron.
Hamid Khoja, the biotechnology company's chief scientific officer said, "unlike traditional treatments, fibroblasts may offer a potential solution aligned with the host biological processes to help regulate immune activity within the spleen, opening new possibilities for managing conditions that involve immune system overload and splenomegaly."
Price: 2.41, Change: -0.09, Percent Change: -3.75
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.